Search results for "personalized"

showing 10 items of 165 documents

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

2014

Antonietta Caruso, Chiara Bellia, Alessia Pivetti, Luisa Agnello, Federica Bazza, Concetta Scazzone, Giulia Bivona, Bruna Lo Sasso, Marcello CiaccioDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, ItalyBackground: The aim of this study was to investigate the effect of two genetic polymorphisms in the coding regions (exon 3 and exon 4) of the EPHX1 gene, ie, 337T>C and 416A>G, respectively, on the metabolism of carbamazepine (CBZ) 10,11-epoxide (the active metabolite of CBZ) by evaluating the variation in serum CBZ 10,11-epoxide levels 4 hours after administration of the drug. Moreover, we reported the genotype frequencies of …

PharmacologyCYP3A4business.industryCarbamazepineEPHX1Pharmacologydrug metabolismGenotype frequency11-epoxidePharmacogenomics and Personalized MedicineIn vivoGenotypemedicineMolecular MedicineCBZ 10EPHX1 genebusinessActive metaboliteDrug metabolismCYP3A4*22medicine.drugOriginal ResearchPharmacogenomics and Personalized Medicine
researchProduct

Copper radiopharmaceuticals for theranostic applications

2018

The growing advancement in nuclear medicine challenges researchers from several different fields to integrate imaging and therapeutic modalities in a theranostic radiopharmaceutical, which can be defined as a molecular entity with readily replaceable radioisotope to provide easy switch between diagnostic and therapeutic applications for efficient and patient-friendly treatment of diseases. For such a reason, the diagnostic and therapeutic potential of all five medical radionuclides of copper have thoroughly been investigated as they boost the hope for development of successful radiotheranostics. To facilitate the mutual understanding between all different specialists working on this multidi…

PharmacologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryPersonalized treatmentNanotechnology02 engineering and technologyGeneral Medicine010402 general chemistry021001 nanoscience & nanotechnologyBiocompatible material01 natural sciencesTheranostic NanomedicineTherapeutic modalities0104 chemical sciencesStructure-Activity RelationshipCopper RadioisotopesDrug DiscoveryAnimalsHumansRadiopharmaceuticals0210 nano-technologyMolecular entityEuropean Journal of Medicinal Chemistry
researchProduct

Why should We Bother? Ethical and Social Issues in Individualized Medicine

2006

Individualized medicine, methodologically rooted in pharmacogenetics and pharmacogenomics, is now venturing into clinical application. Prescribing the right drug in the right dose to the right patient according to specific health needs and individual characteristics is a core mission of individualized medicine. The intrinsic values of this mission are so self-evident that--at first glance--the ethical and social issues raised by individualized medicine seem to be negligible. However, the translation of pharmacogenetics and pharmacogenomics into clinical routine not only requires the collection and evaluation of large amounts of individual genetic data, but also heralds the need for further …

PharmacologySocial Responsibilitymedicine.medical_specialtySocial Valuesbusiness.industryeducationClinical BiochemistryMEDLINEBioethicsSocial value orientationsSocial issuesPharmacogeneticsFamily medicinePharmacogenomicsDrug DiscoverymedicineHumansMolecular MedicineNormativeEthics MedicalEngineering ethicsPersonalized medicinebusinessSocial responsibilityCurrent Drug Targets
researchProduct

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

2021

Background Despite its proven activity as third-line treatment in gastrointestinal stromal tumors (GIST), regorafenib can present a poor tolerability profile which often leads to treatment modifications and transient or permanent discontinuation; thus, in clinical practice physicians usually adopt various dosing and interval schedules to counteract regorafenib-related adverse events and avoid treatment interruption. The aim of this real-world study was to investigate the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST, in comparison with the standard schedule (160 mg daily, 3-weeks-on, 1-week-off). Patients and methods Institutional registries a…

Phenylurea CompoundOncologyCancer Researchmedicine.medical_specialtyScheduleStromal cellPyridinesGastrointestinal Stromal TumorsPyridinePersonalized treatmentchemical and pharmacologic phenomenaMultikinase inhibitorchemistry.chemical_compoundQuality of lifeRetrospective Studieimmune system diseaseshemic and lymphatic diseasesInternal medicineRegorafenibmedicineHumansOriginal ResearchRetrospective StudiesGiSTbusiness.industryPhenylurea Compoundstoxicityhemic and immune systemspersonalized treatmentdigestive system diseasesquality of lifeOncologychemistryregorafenibGIST; personalized treatment; quality of life; regorafenib; toxicity; Humans; Phenylurea Compounds; Pyridines; Retrospective Studies; Gastrointestinal Stromal TumorsbusinessHumanGISTESMO Open
researchProduct

Treatment options in obstructive sleep apnea

2022

AbstractTreatment of OSA with CPAP is currently the recommended treatment and has the greatest evidence of efficacy on AHI, symptoms and comorbidities. Symptomatic patients with moderate-severe OSA generally have good adherence to CPAP therapy, while those with mild OSA, female, young and generally paucisymptomatic, have lower CPAP adherence, especially in the medium and long term. The recent identification of different clinical and pathophysiological phenotypes of OSA has paved the way for alternative treatments to CPAP, leading to an increasingly personalized therapy. Weight loss and lifestyle modifications are highly recommended in all obese or overweight patients. Mandibular advancement…

Physiological phenotypeSleep Apnea ObstructiveContinuous Positive Airway PressureSettore MED/10 - Malattie Dell'Apparato RespiratorioPersonalized medicineCPAP adherenceNon-PAP treatmentTreatment OutcomeClinical phenotypeWeight LossEmergency MedicineInternal MedicineHumansFemaleLife StyleMandibular AdvancementInternal and Emergency Medicine
researchProduct

2021

Abstract This paper reports on a teaching innovation using participant-generated drawings. Experienced managers were asked to produce a drawing to illustrate their work from an accounting perspective. The drawings were then used to make the managerial context of the participants the explicit starting point for personalized executive learning. This study is the first in the sphere of accounting education and research to take drawing seriously as a learning method. The results of the experiment show how drawing can be further used as a tool in management education by facilitating the visualization of the managerial contexts participants work within.

Point (typography)business.industry05 social sciencesPerspective (graphical)050301 educationContext (language use)Accounting050201 accountingPersonalized learningAccounting educationEducationVisualizationWork (electrical)Accounting0502 economics and businessLearning methodsbusinessPsychology0503 educationJournal of Accounting Education
researchProduct

Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129

2019

WOS: 000474931400001

Project Report0301 basic medicinemedicine.medical_specialtyBiochemistry & Molecular BiologyKnowledge managementlcsh:QH426-470BIOMARKERSbest practices and guidelines; cardiovascular disease; personalized medicine; transcriptomics; translational researchContext (language use)Translational researchDisease030204 cardiovascular system & hematologyBiologyBiochemistryLONG NONCODING RNAS03 medical and health sciencestranscriptomics0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCIRCULATING MICRORNASTARGETScardiovascular diseaseGeneticsmedicineCost actionSet (psychology)Molecular BiologyComputingMilieux_MISCELLANEOUSGenetics & HeredityScience & Technologybusiness.industryCardiovascular system -- DiseasesPublic healthMedicine -- Research -- International cooperationpersonalized medicine3. Good healthlcsh:Genetics030104 developmental biologyAction (philosophy)PERSPECTIVEStranslational researchPersonalized medicineTranslational research biomedicalbest practices and guidelinesbusinessTranscriptomeLife Sciences & Biomedicine
researchProduct

The EU-funded I3LUNG Project:Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

2023

Although immunotherapy (IO) has changed the paradigm for the treatment of patients with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50% of treated patients experience a long-term benefit from IO. Furthermore, the identification of the 30 to 50% of patients who respond remains a major challenge, as programmed Death-Ligand 1 (PD-L1) is currently the only biomarker used to predict the outcome of IO in NSCLC patients despite its limited efficacy. Considering the dynamic complexity of the immune system-tumor microenvironment (TME) and its interaction with the host's and patient's behavior, it is unlikely that a single biomarker will accurately predict a patient's outcomes. …

Pulmonary and Respiratory MedicineCancer ResearchArtificial intelligenceOncologyNon-small cell lung cancerPredictive biomarkersMachine learningPersonalized medicine
researchProduct

Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?

2016

In the majority of cases, asthma and chronic obstructive pulmonary disease (COPD) are two clearly distinct disease entities. However, in some patients there may be significant overlap between the two conditions. This constitutes an important area of concern because these patients are generally excluded from randomised controlled trials (mostly because of smoking history in the case of asthma or because of significant bronchodilator reversibility in the case of COPD). As a result, their pathobiology, prognosis and response to therapy are largely unknown. This may lead to suboptimal management and can limit the development of more personalised therapeutic options. Emerging genetic and molecul…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPlacebo-controlled studyAlternative medicinePHENOTYPESAIRWAY DISEASEDiseasePLACEBO-CONTROLLED TRIALOBSTRUCTIVE PULMONARY-DISEASETHERAPYCOPD MechanismsDOUBLE-BLINDPulmonary Disease Chronic ObstructiveAsthma; COPD MechanismsTerminology as TopicmedicineHumansDiseasePrecision MedicineIntensive care medicineINDEXAsthmaCLUSTER-ANALYSISCOPDbusiness.industrySystems Biologymedicine.diseaseAsthmaLUNG-FUNCTIONSystems medicineEXACERBATIONSPhenotypePhysical therapyHealth educationPersonalized medicinebusinessThorax
researchProduct

Sin registro de donantes de gametos: cerca de treinta años esperando su creación

2015

En este estudio planteamos la necesidad de un registro de donantes de gametos y presentamos las claves de por qué no existe aún en España un registro de estas características. Frente a las consecuencias negativas que se pueden derivar de la inexistencia de este tipo de registro, reflexionamos sobre la conveniencia y oportunidad de crear una red de registros de donantes para la medicina del siglo XXI In this study it is stated the idea that a register for gametes donors is necessary and we identify the key points explaining why such a register does not exist in Spain. Facing the negative consequences derived from the nonexistence of register for gametes donors, we make a mental construction …

Register (sociolinguistics)Registers for gametes donorsGeographyRegulación nacional y comparadaMedicina personalizadaNational and comparative regulationHumanitiesPersonalized medicineGenealogyRegistros de donantes de gametos
researchProduct